- Home
- ICU vs SNGX Comparison
ICU vs SNGX Comparison
Compare ICU & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICU
- SNGX
- Stock Information
- Founded
- ICU 2018
- SNGX 1987
- Country
- ICU United States
- SNGX United States
- Employees
- ICU N/A
- SNGX N/A
- Industry
- ICU Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ICU Health Care
- SNGX Health Care
- Exchange
- ICU Nasdaq
- SNGX Nasdaq
- Market Cap
- ICU 8.9M
- SNGX 7.4M
- IPO Year
- ICU N/A
- SNGX 1987
- Fundamental
- Price
- ICU $1.75
- SNGX $2.35
- Analyst Decision
- ICU
- SNGX
- Analyst Count
- ICU 0
- SNGX 0
- Target Price
- ICU N/A
- SNGX N/A
- AVG Volume (30 Days)
- ICU 24.8K
- SNGX 619.7K
- Earning Date
- ICU 11-13-2024
- SNGX 03-14-2025
- Dividend Yield
- ICU N/A
- SNGX N/A
- EPS Growth
- ICU N/A
- SNGX N/A
- EPS
- ICU N/A
- SNGX N/A
- Revenue
- ICU $68,000.00
- SNGX $364,183.00
- Revenue This Year
- ICU N/A
- SNGX N/A
- Revenue Next Year
- ICU $358.72
- SNGX $76.64
- P/E Ratio
- ICU N/A
- SNGX N/A
- Revenue Growth
- ICU N/A
- SNGX N/A
- 52 Week Low
- ICU $1.68
- SNGX $1.83
- 52 Week High
- ICU $42.93
- SNGX $14.88
- Technical
- Relative Strength Index (RSI)
- ICU 34.18
- SNGX 34.04
- Support Level
- ICU $1.68
- SNGX $2.03
- Resistance Level
- ICU $2.01
- SNGX $3.44
- Average True Range (ATR)
- ICU 0.13
- SNGX 0.33
- MACD
- ICU -0.01
- SNGX -0.08
- Stochastic Oscillator
- ICU 14.00
- SNGX 19.39
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).